- Home
- About
- Team
- Today's Market
- Premium
- Research it
- Outlook
- Portfolio
- Mobile
- Trust Equitymaster
- Help
- Free Reports
MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- GLENMARK PHARMACEUTICALS LIMITED (pharmaceuticals)
- GLENMARK PHARMACEUTICALS LIMITED Financial Data
Glenmark Pharma Fact Sheet 
(GLPH)
Here is the latest financial fact sheet of Glenmark Pharma. For more details, see the Glenmark Pharma quarterly results and Glenmark Pharma share price and chart. For a sector overview, read our pharmaceuticals sector report.
GLENMARK PHARMA Price History
| % ch | % | -1.5 |
| No. of shares | m | 271.28 |
| % ch week | % | 2.7 |
| % ch 1-mth | % | -10.7 |
| % ch 12-mth | % | -0.7 |
| 52 week H/L | Rs | 711.6/483.6 |
GLENMARK PHARMA Financials
| No. of Mths Year Ending |
12 Mar-14* |
12 Mar-15* |
12 Mar-16* |
12 Mar-17* |
12 Mar-18* |
5-Yr Chart Click to enlarge
|
|---|
| GLENMARK PHARMA EQUITY SHARE DATA | |||||||
|---|---|---|---|---|---|---|---|
| High | Rs | 612 | 879 | 1,262 | 993 | 930 | |
| Low | Rs | 464 | 752 | 672 | 729 | 517 | |
| Sales per share (Unadj.) | Rs | 221.4 | 244.4 | 271.1 | 325.5 | 322.6 | |
| Earnings per share (Unadj.) | Rs | 20.1 | 17.5 | 26.3 | 39.3 | 28.5 | |
| Diluted earnings per share | Rs | 20.1 | 17.5 | 27.4 | 40.9 | 29.6 | |
| Cash flow per share (Unadj.) | Rs | 28.1 | 27.1 | 34.6 | 48.7 | 39.2 | |
| Dividends per share (Unadj.) | Rs | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | |
| Adj. dividends per share | Rs | 2.00 | 2.00 | 2.08 | 2.08 | 2.08 | |
| Dividend yield (eoy) | % | 0.4 | 0.2 | 0.2 | 0.2 | 0.3 | |
| Book value per share (Unadj.) | Rs | 110.0 | 86.1 | 128.6 | 159.2 | 183.0 | |
| Adj. book value per share | Rs | 110.0 | 86.1 | 133.8 | 165.6 | 190.3 | |
| Shares outstanding (eoy) | m | 271.22 | 271.29 | 282.16 | 282.17 | 282.17 | |
| Bonus/Rights/Conversions | - | - | - | ESOP | - | ||
| Price / Sales ratio | x | 2.4 | 3.3 | 3.6 | 2.6 | 2.2 | |
| Avg P/E ratio | x | 26.7 | 46.6 | 36.7 | 21.9 | 25.4 | |
| P/CF ratio (eoy) | x | 19.1 | 30.1 | 27.9 | 17.7 | 18.5 | |
| Price / Book Value ratio | x | 4.9 | 9.5 | 7.5 | 5.4 | 4.0 | |
| Dividend payout | % | 9.9 | 11.4 | 7.6 | 5.1 | 7.0 | |
| Avg Mkt Cap | Rs m | 145,889 | 221,284 | 272,778 | 242,991 | 204,206 | |
| No. of employees | `000 | NA | 9.5 | 10.0 | 13.0 | 13.7 | |
| Total wages/salary | Rs m | 10,262 | 12,024 | 13,782 | 16,408 | 18,718 | |
| Avg. sales/employee | Rs Th | NM | 6,961.1 | 7,630.5 | 7,083.9 | 6,636.8 | |
| Avg. wages/employee | Rs Th | NM | 1,262.5 | 1,374.8 | 1,265.4 | 1,364.7 | |
| Avg. net profit/employee | Rs Th | NM | 499.0 | 741.2 | 855.1 | 586.1 | |
| GLENMARK PHARMA INCOME DATA | |||||||
|---|---|---|---|---|---|---|---|
| Net Sales | Rs m | 60,052 | 66,298 | 76,496 | 91,857 | 91,031 | |
| Other income | Rs m | 115 | 219 | 200 | 374 | 914 | |
| Total revenues | Rs m | 60,167 | 66,516 | 76,696 | 92,230 | 91,945 | |
| Gross profit | Rs m | 10,908 | 10,225 | 14,372 | 20,367 | 16,154 | |
| Depreciation | Rs m | 2,168 | 2,600 | 2,343 | 2,644 | 3,019 | |
| Interest | Rs m | 1,886 | 1,902 | 1,789 | 2,373 | 2,856 | |
| Profit before tax | Rs m | 6,969 | 5,943 | 10,440 | 15,724 | 11,193 | |
| Minority Interest | Rs m | 0 | 0 | 0 | 0 | 0 | |
| Prior Period Items | Rs m | 0 | 0 | 0 | 0 | 0 | |
| Extraordinary Inc (Exp) | Rs m | 0 | 0 | 0 | -810 | 0 | |
| Tax | Rs m | 1,513 | 1,190 | 3,009 | 3,827 | 3,155 | |
| Profit after tax | Rs m | 5,456 | 4,752 | 7,430 | 11,088 | 8,039 | |
| Gross profit margin | % | 18.2 | 15.4 | 18.8 | 22.2 | 17.7 | |
| Effective tax rate | % | 21.7 | 20.0 | 28.8 | 24.3 | 28.2 | |
| Net profit margin | % | 9.1 | 7.2 | 9.7 | 12.1 | 8.8 | |
| GLENMARK PHARMA BALANCE SHEET DATA | |||||||
|---|---|---|---|---|---|---|---|
| Current assets | Rs m | 47,627 | 53,199 | 59,043 | 68,746 | 69,887 | |
| Current liabilities | Rs m | 29,492 | 37,111 | 39,993 | 27,027 | 32,879 | |
| Net working cap to sales | % | 30.2 | 24.3 | 24.9 | 45.4 | 40.7 | |
| Current ratio | x | 1.6 | 1.4 | 1.5 | 2.5 | 2.1 | |
| Inventory Days | Days | 57 | 70 | 75 | 85 | 81 | |
| Debtors Days | Days | 131 | 138 | 119 | 96 | 93 | |
| Net fixed assets | Rs m | 30,357 | 17,445 | 21,416 | 24,132 | 28,892 | |
| Share capital | Rs m | 271 | 271 | 282 | 282 | 282 | |
| "Free" reserves | Rs m | 21,415 | 23,086 | 36,014 | 44,643 | 51,353 | |
| Net worth | Rs m | 29,833 | 23,357 | 36,296 | 44,925 | 51,635 | |
| Long term debt | Rs m | 24,287 | 25,744 | 24,873 | 45,363 | 41,418 | |
| Total assets | Rs m | 86,336 | 87,429 | 101,929 | 117,639 | 125,954 | |
| Interest coverage | x | 4.7 | 4.1 | 6.8 | 7.6 | 4.9 | |
| Debt to equity ratio | x | 0.8 | 1.1 | 0.7 | 1.0 | 0.8 | |
| Sales to assets ratio | x | 0.7 | 0.8 | 0.8 | 0.8 | 0.7 | |
| Return on assets | % | 8.5 | 7.6 | 9.0 | 11.4 | 8.6 | |
| Return on equity | % | 18.3 | 20.3 | 20.5 | 24.7 | 15.6 | |
| Return on capital | % | 16.4 | 16.0 | 20.0 | 19.1 | 15.1 | |
| Exports to sales | % | 11.7 | 44.8 | 43.2 | 0 | 0 | |
| Imports to sales | % | 1.0 | 7.1 | 7.4 | 0 | 0 | |
| Exports (fob) | Rs m | 7,039 | 29,720 | 33,044 | 0 | 0 | |
| Imports (cif) | Rs m | 579 | 4,680 | 5,672 | 0 | 0 | |
| Fx inflow | Rs m | 8,528 | 31,299 | 36,945 | 56,152 | 36,317 | |
| Fx outflow | Rs m | 3,641 | 10,856 | 61,066 | 8,084 | 9,720 | |
| Net fx | Rs m | 4,888 | 20,443 | -24,122 | 48,068 | 26,598 | |
| GLENMARK PHARMA CASH FLOW | |||||||
|---|---|---|---|---|---|---|---|
| From Operations | Rs m | 8,537 | 4,817 | 3,449 | 6,574 | 16,481 | |
| From Investments | Rs m | -3,681 | -5,400 | -8,802 | -7,124 | -10,133 | |
| From Financial Activity | Rs m | -980 | 1,992 | 6,986 | 5,432 | -4,685 | |
| Net Cashflow | Rs m | 1,896 | -311 | 934 | 1,992 | 1,770 | |
Share Holding
|
Company Information
|
|||||||||||||||||||||||||||||||||||||||||
| CHM: Glenn Saldanha (MD) | COMP SEC: Sanjay Kumar Chowdhary | YEAR OF INC: 1977 | BSE CODE: 532296 | FV (Rs): 1 | DIV YIELD (%): 0.3 |
Read: GLENMARK PHARMA 2017-18 Annual Report Analysis
More Pharmaceuticals Company Fact Sheets: SHASUN PHARMA PANACEA BIOTECH INDOCO REMEDIES TORRENT PHARMA ORCHID PHARMA LTD
Compare GLENMARK PHARMA With: SHASUN PHARMA PANACEA BIOTECH INDOCO REMEDIES TORRENT PHARMA ORCHID PHARMA LTD
Compare GLENMARK PHARMA With: ADCOCK INGRAM (S. Africa) MYLAN (US) ACTAVIS (US) TEVA PHARMA (Israel)
|
| |
Today's Market
Sensex Ends 297 Points Higher; Energy and Realty Stocks Witness Buying(Closing)
Share markets in India continued their momentum during closing hours and ended the day on a positive note. Sectoral indices were trading on a positive note, with stocks in the energy sector.
Views on news
GLENMARK PHARMA 2017-18 Annual Report Analysis (Annual Result Update)
Sep 27, 2018 | Updated on Sep 27, 2018Here's an analysis of the annual report of GLENMARK PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of GLENMARK PHARMA. Also includes updates on the valuation of GLENMARK PHARMA.
GLENMARK PHARMA Announces Quarterly Results (1QFY19); Net Profit Down 30.1% (Quarterly Result Update)
Aug 13, 2018 | Updated on Aug 13, 2018For the quarter ended June 2018, GLENMARK PHARMA has posted a net profit of Rs 2 bn (down 30.1% YoY). Sales on the other hand came in at Rs 22 bn (down 8.4% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.
GLENMARK PHARMA Announces Quarterly Results (4QFY18); Net Profit Down 6.6% (Quarterly Result Update)
May 31, 2018 | Updated on May 31, 2018For the quarter ended March 2018, GLENMARK PHARMA has posted a net profit of Rs 2 bn (down 6.6% YoY). Sales on the other hand came in at Rs 23 bn (down 7.2% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.
Aster DM Healthcare (IPO)
Feb 10, 2018Should you subscribe to the IPO of Aster DM Healthcare Ltd?
Shalby Ltd. (IPO)
Dec 2, 2017Should you subscribe to the IPO of Shalby Ltd?
More Views on NewsMost Popular
Don't Panic in This Falling Market... Do This Instead(The 5 Minute Wrapup)
Oct 5, 2018Find companies with long term durable moats, which are correcting with the current broader market sell-off.
Why You Should Be Excited, Not Sad, About the 30% Small Cap Crash(Profit Hunter)
Oct 4, 2018Smallcaps have corrected over 30% since the beginning of the year. Find out why Richa Agarwal views this as an opportunity rather than a threat.
Taxpayers to pay salaries of CEOs/CIOs of Mutual Funds(The Honest Truth)
Oct 5, 2018Ajit Dayal on the crisis in the market and in the mutual fund industry.
Why Are Investors In Sundaram Small Cap Fund Anxious(Outside View)
Oct 3, 2018A small cap fund that aims to capitalise on emerging businesses and catch them young. However, its failure in keeping volatility under check is making its investors anxious.
Biggest Corrections in the Stock of Infibeam Avenues(Chart Of The Day)
Oct 3, 2018Infibeam plunged over 70% last week. This was the second biggest single-day fall. But Infibeam witnessed such sharp falls earlier.
More|
| |
TRACK GLENMARK PHARMA
- Track your investment in GLENMARK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON GLENMARK PHARMA
GLENMARK PHARMA 8-QTR ANALYSIS
COMPARE GLENMARK PHARMA WITH
OTHER USEFUL LINKS
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
FOLLOW
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.